Aardvark Therapeutics
AARD
72 hedge funds and large institutions have $54.3M invested in Aardvark Therapeutics in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 24 reducing their positions, and 24 closing their positions.
41% more capital invested
Capital invested by funds: $38.5M → $54.3M (+$15.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.52% less ownership
Funds ownership: 46.75% → 43.24% (-3.5%)
9% less funds holding
Funds holding: 79 → 72 (-7)
17% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 24
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
87% less call options, than puts
Call options by funds: $87K | Put options by funds: $670K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.85M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.62M |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$320K |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$233K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.83M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$1.19M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$746K |
| 4 |
State Street
Boston,
Massachusetts
|
-$654K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$571K |
AARD Hedge Fund Activity: Q2 2026 in Review
72 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q2 2026, worth a combined $54.3M — up 41% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AARD and 19 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 20 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.85M. The largest seller was BlackRock, cutting an estimated $2.83M.
- 72 institutional investors held Aardvark Therapeutics (AARD) as of Q2 2026, down from 79 in Q1 2026.
- Funds reported $54.3M of Aardvark Therapeutics stock for Q2 2026, up 41% quarter-over-quarter.
- 19 funds opened new Aardvark Therapeutics positions in Q2 2026 and 24 closed out, a net change of -5 holders.
- The largest Aardvark Therapeutics buyer in Q2 2026 was EcoR1 Capital, an estimated $1.85M added.
- The largest Aardvark Therapeutics seller in Q2 2026 was BlackRock, an estimated $2.83M sold.
Based on aggregated 13F filings for Q2 2026.